Using AI to discover molecular markers identifying patients more likely to have clinical benefit to the treatment can reduce time taken to conduct research and trial
"Patient samples are collected in both diseased and healthy states and are processed by our high throughput mass spectrometer workflow. Here we analyze the biological activity and make up the sample through adaptive omics. This includes the genome, proteome, lipidome and metabolome. We also look at mitochondrial function, oxidative states, and ATP production to examine how the cells are functioning. The process produces trillions of data points from a single sample. The data is then combined with patient clinical information and analyzed by our proprietary artificial intelligence machine learning analytics program. This combination of systems biology and artificial intelligence is the BERG Interrogative Biology® platform."
Genome, proteome, lipidome and metabolome data Trillions of data points from each sample
Research; Results not yet available